Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

J Med Econ. 2018 Dec;21(12):1148-1149. doi: 10.1080/13696998.2018.1528979. Epub 2018 Oct 17.

Authors

Lin Liang¹, David Bin-Chia Wu¹, Mohamed Ismail Abdul Aziz¹, Raymond Wong², David Sim³, Kui Toh Gerard Leong⁴, Yong Quek Wei⁵, Doreen Tan⁶, Kwong Ng¹

Affiliations

¹ a Agency for Care Effectiveness , Ministry of Health , Singapore.
² b Department of Cardiology , National University Heart Centre , Singapore.
³ c Department of Cardiology , National Heart Centre , Singapore.
⁴ d Department of Cardiology , Changi General Hospital , Singapore.
⁵ e Department of Cardiology , Tan Tock Seng Hospital , Singapore.
⁶ f Department of Pharmacy , Khoo Teck Puat Hospital , Singapore.

PMID: 30255725
DOI: 10.1080/13696998.2018.1528979

No abstract available

Publication types

Comment

MeSH terms

Aminobutyrates
Biphenyl Compounds
Cost-Benefit Analysis
Drug Combinations
Enalapril*
Heart Failure*
Humans
Stroke Volume
Tetrazoles
Valsartan

Substances

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Tetrazoles
Enalapril
Valsartan
sacubitril and valsartan sodium hydrate drug combination